Oncolytics Biotech (ONCY) Q1 2026 earnings summary

Executive summary

• Focused on advancing pelareorep, an immunotherapeutic agent, for GI cancers, with ongoing and planned registration-enabling studies in metastatic colorectal, anal, and pancreatic cancers.

• Fast Track Designation granted for pelareorep in second-line KRAS-mutant mCRC; pivotal studies in SCAC and PDAC under FDA alignment.

• Sufficient drug supply for clinical programs; manufacturing and process validation activities ongoing for commercial readiness.

Financial highlights

• Net loss of $9.2 million for Q1 2026, compared to $4.7 million in Q1 2025, driven by higher R&D and G&A expenses.

• R&D expenses rose to $4.6 million (up $1.8 million year-over-year), mainly due to increased personnel and clinical trial costs.

• G&A expenses increased to $4.7 million (up $2.5 million year-over-year), reflecting higher public company and personnel costs.

• Cash and cash equivalents were $5.5 million as of March 31, 2026.

• Raised $7.6 million net from ATM equity offerings in Q1 2026; additional $2.3 million net raised post-quarter via new sales agreement.

Outlook and guidance

• Current cash resources sufficient for near-term milestones but not for twelve months of planned operations; substantial doubt about ability to continue as a going concern.

• Plans to raise additional capital through equity sales and strategic collaborations; may need to reduce or delay R&D if funding is not secured.

• 2026 focus on advancing randomized second-line mCRC study and evaluating partnership options for PDAC and SCAC programs.